Novel immunotherapy against several tumors including neuronal and brain tumors

A fusion protein comprising the peptide of SEQ ID NO:

• 6 adjoined at the N-terminus and/or the C-terminus by one or more heterologous peptides, or a pharmaceutically acceptable salt thereof.

An acylated peptide consisting of SEQ ID NO:

• 6 or a pharmaceutically acceptable salt thereof.

A pegylated peptide consisting of SEQ ID NO:

• 6 or a pharmaceutically acceptable salt thereof.

A method for producing activated cytotoxic T lymphocytes (CTL), the method comprising

• contacting in vitro CTL with antigen-loaded human class I or II MHC molecules expressed on the surface of a suitable antigen-presenting cell or an artificial construct mimicking an antigen-presenting cell for a period of time sufficient to activate said CTL in an antigen specific manner, wherein said antigen is a peptide comprising SEQ ID NO:
• 6 wherein said peptide is not an underlying full-length polypeptide